Form 4: Ionis Pharmaceuticals CEO Sells Shares Under Pre-Arranged Trading Plan
Insider Transaction Report
Ionis Pharmaceuticals CEO Brett P. Monia sold 1,160 shares of common stock for a weighted average price of $41.7381 per share on July 11, 2025, as part of a pre-arranged Rule 10b5-1 trading plan.
Summary
- Brett P. Monia, Chief Executive Officer and Director of Ionis Pharmaceuticals Inc. (IONS), reported a transaction involving the company's common stock.
- On July 11, 2025, Monia sold 1,160 shares of Ionis Pharmaceuticals common stock.
- The shares were sold at a weighted average price of $41.7381 per share, with individual transaction prices ranging from $41.67 to $41.79.
- This sale was executed pursuant to a Rule 10b5-1 trading plan, which was adopted by Monia on August 13, 2024.
- Following this transaction, Brett P. Monia beneficially owns 179,820 shares of Ionis Pharmaceuticals common stock directly.
Sentiment
Score: 5
Explanation: The Form 4 reports a routine insider stock sale executed under a Rule 10b5-1 trading plan, which is a pre-scheduled transaction. This type of filing is generally considered neutral as it does not reflect new information about the company's performance or outlook, but rather a pre-determined liquidity event for the insider.
Positives
- The sale was conducted under a Rule 10b5-1 trading plan, which indicates a pre-scheduled transaction designed to avoid accusations of trading on material non-public information and enhances transparency.
Negatives
- A company insider, the Chief Executive Officer, sold shares, which some investors might interpret as a lack of confidence, although the sale was pre-planned under a Rule 10b5-1 trading plan.
Risks
- NA
Future Outlook
NA
Management Comments
- The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.
Industry Context
NA
Comparison to Industry Standards
- NA
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
Legal Proceedings
- NA
Related Party Transactions
- NA
Stakeholder Impact
- Shareholders: The sale by a CEO, even if pre-planned, might be viewed with slight caution by some shareholders, though the Rule 10b5-1 plan mitigates concerns about opportunistic selling. It reduces the CEO's direct ownership slightly.
Next Steps
- The reporting person undertakes to provide detailed information on share sales within the specified price range upon request from Ionis Pharmaceuticals, its security holders, or the SEC staff.
Key Dates
| Date | Description |
|---|---|
| August 13, 2024 | Date Brett P. Monia adopted the Rule 10b5-1 Trading Plan. |
| July 11, 2025 | Date of the reported transaction where shares were sold. |
| July 14, 2025 | Date the Form 4 was signed by the attorney-in-fact for Brett P. Monia. |
Recommendation
holdKeywords
Ionis Pharmaceuticals, IONS, Brett P. Monia, CEO, Director, Insider Trading, Form 4, SEC Filing, Stock Sale, 10b5-1 Plan, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.